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Objective: To examine the role of an IGF-I gene promoter polymorphism in the prevalence of radiographic
osteoarthritis (ROA), and study its interaction with the COL2A1 gene.
Methods: Individuals genotyped for IGF-I (n = 1546) and COL2A1 gene polymorphisms (n = 808) were
selected from a random sample (n = 1583) derived from the Rotterdam study. The presence of ROA was
defined as a Kellgren score of 2 or more in at least one of four joints (knee, hip, hand, and spine).
Genotype specific odds ratios (OR) were adjusted for age, sex, body mass index, and bone mineral
density using logistic regression. Interaction with the COL2A1 genotype was tested.
Results: Overall, no association was found between the IGF-I polymorphism and ROA. In subjects aged 65
years or younger (n = 971), the prevalence of ROA increased with the absence of the 192 base pair (bp)
allele (p for trend = 0.03). Compared with homozygotes for the 192 bp allele, the prevalence of ROA was
1.4 times higher in heterozygotes (95% confidence interval, 1.0 to 1.8) and 1.9 times higher in non-
carriers (1.1 to 3.3). There was evidence of interaction between the IGF-I and COL2A1 genes. Individuals
with the risk genotype of both genes had an increased prevalence of ROA (OR 3.4 (1.1 to 10.7)). No
effect was observed in subjects older than 65 years.
Conclusions: Subjects with genetically determined low IGF-I expression (non-carriers of the 192 bp allele)
may be at increased risk of ROA before the age of 65 years. Furthermore, an interaction between the IGF-I
and COL2A1 genes is suggested.
O
steoarthritis, the most common form of arthritis in
the elderly,1 2 is characterised by progressive degen-
eration of articular cartilage, along with subchondral
bone changes leading to the formation of osteophytes.3
Osteoarthritis is a complex disease4 with clearly described
environmental factors and a strong genetic influence.
Familial aggregation has been recognised for Heberden’s
nodes5 and for early onset generalised osteoarthritis in
combination with Heberden’s nodes.6 Recently, twin and
sibling pair studies have revealed a considerable genetic
contribution to the development of osteoarthritis, with
heritability estimates ranging from 30% to 78% at different
joints.7–11 Linkage to several chromosomal regions has also
been reported in different studies.12–16 Consequently, it is
expected that several genes which regulate the formation,
degradation, and repair of articular cartilage and subchondral
bone metabolism may determine the occurrence of osteo-
arthritis. However, the specific underlying genetic factors and
mechanisms in the development of osteoarthritis remain to
be determined.
Insulin-like growth factor I (IGF-I) is a polypeptide
mediator with a potent anabolic impact on cartilage home-
ostasis. Several studies17 18 have highlighted the importance
of IGF-I in promoting cartilage growth and development,
implying a potential role of IGF-I in the aetiology of
osteoarthritis. Circulating IGF-I is significantly decreased
with advancing age.19 An age related decline in the ability of
IGF-I to stimulate chondrocytes to produce articular matrix
components has also been demonstrated.20 Findings of the
relation between osteoarthritis and either serum or synovial
IGF-I concentrations are still conflicting.21–24 A problem with
the interpretation of these findings is that IGF-I concentra-
tions are often assessed in blood, and the values may change
because of joint or other pathology. Study of the gene
polymorphism that regulates the protein levels is a useful
method that avoids this problem.
We previously reported a polymorphism in the promoter
region of the IGF-I gene associated with an increased
prevalence of radiological osteoarthritis (ROA) in the subset
data of the Rotterdam study.25 In a subsequent study, we
found that absence of the 192 base pair (bp) (wild type) allele
of this polymorphism was associated with lower serum IGF-I
concentrations in our population,26 suggesting that this allele
has functional properties.
Collagen type II a1 (COL2A1), which constitutes 90% of
the collagen in the hyaline articular cartilage and inter-
vertebral disk, is another important protein involved in the
development of osteoarthritis. Mutations in the COL2A1 gene
may be related to structural failure of the protein over time,
and thus to the occurrence of osteoarthritis. We previously
found a VNTR (variable number of tandem repeats)
polymorphism located 1.35 kb downstream of the COL2A1
gene associated with an increased risk for ROA,27 28 although
this findings was not confirmed by others.29 30
Given the conflicting findings over the role of the IGF-I
protein in osteoarthritis and problems with the assessment of
in vivo tissue IGF-I concentrations in humans, we studied the
192 bp allele of the IGF-I promoter polymorphism in relation
to osteoarthritis, assuming that this polymorphism deter-
mines IGF-I expression both in blood and in cartilage. We
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: BMD, bone mineral density; BMI, body mass index;
PCR, polymerase chain reaction; ROA, radiographic osteoarthritis;
VNTR, variable number of tandem repeats
544
www.annrheumdis.com
also studied the interaction of this genetic polymorphism
with the COL2A1 polymorphism that we had earlier found to
be associated with osteoarthritis.27
METHODS
Study population
The study was part of the Rotterdam Study, a prospective
population based investigation of the determinants and
prognosis of chronic diseases in 7983 elderly people. The
design of the study has been described elsewhere.31 Written
informed consent was obtained from each participant. The
Rotterdam Study was approved by the medical ethics
committee of Erasmus University Medical School.
Previously, a random sample of 1583 subjects from the
Rotterdam Study, aged 55 to 70 years, was assessed for ROA
and disk degeneration.10 We included in the present study
1554 individuals from that random group who had the
genotype for the IGF-I polymorphism and 816 who had the
genotype for COL2A1 gene polymorphism. Eight subjects
were excluded because of absent scoring of radiographs at
sites considered for ROA assessment. The final study
population comprised 1546 individuals in the IGF-I associa-
tion analysis and 808 individuals in the gene interaction
analysis.
Measurements
Age was computed at baseline and was used to stratify the
individuals into two groups: cases aged 65 years or younger
with early onset osteoarthritis (n = 971) and cases older than
65 years with late onset osteoarthritis (n = 575). Standing
body height and body weight were measured with the
subjects wearing light indoor clothes and no shoes. Body
mass index (BMI) was calculated dividing weight (kg) by the
square of height (m). Bone mineral density (BMD) measure-
ments of the neck of the femur were made using dual energy
x ray absorptiometry (Lunar DPX-L densitometer) as
described previously.32 Radiographic measurement and scor-
ing techniques were done at baseline as described previously
for knee and hip33 and for hand and spine.10 Definite ROA at a
particular joint site was defined as a Kellgren score34 of 2 or
more. In the present study, ROA cases were defined as having
at least one of the four joint sites affected—that is, knee, hip,
hand, or spine. ROA controls were defined as having none of
the four joint sites affected.
Genotyping
Genomic DNA was isolated from all blood samples.
Genotypes for the dinucleotide polymorphic cytosine–ade-
nine (CA) repeats 1 kb upstream of the human IGF-I gene
were determined according to Weber and May.35 Genotypes
of the VNTR polymorphism located 1.35 kb downstream of
the COL2A1 gene were determined according to Berg and
Olaisen36 in the same sample of subjects in whom the IGF-I
polymorphism was genotyped. Polymerase chain reaction
(PCR) conditions, primers, and genotype analysis were
undertaken as described previously for the IGF-I gene
polymorphism26 and for the COL2A1 gene polymorphism.27
Alleles were labelled for the IGF-I gene polymorphism
according to the length of the PCR product, and three
genotypes were assigned to the individuals according to the
presence or absence of the 192 bp (wild type) allele as
follows: 192 bp homozygotes, 192 bp heterozygotes, and non-
carriers of the 192 bp allele. For the COL2A1 gene
polymorphism we used Berg and Olaisen nomenclature36
and looked for the presence or absence of the 13R1 allele.27
Earlier, we used heteroduplex analysis (HA)37 38 to study the
relation between the COL2A1 gene and knee osteoarthritis.28
This method allows separation of the SS allele 13R1 into two
main alleles (4A and 4B). Based on these findings, we further
evaluated the interaction of the 4A and 4B alleles with the
192 bp allele of the IGF-I gene in ROA in 591 subjects from
our study population with available HA genotypes.
Statistical analysis
Baseline measurements were compared between ROA cases
and controls using t tests for independent samples and the x2
test (where appropriate). All genotype frequencies of the IGF-
I and COL2A1 genes were in Hardy-Weinberg equilibrium
proportions. Prevalence of ROA in carriers and non-carriers
was compared using odds ratios (OR) with 95% confidence
intervals (CI) obtained from logistic regression, adjusted for
age, sex, BMI, and BMD. The product term of the number of
192 bp alleles in the IGF-I genotypes and the presence or
absence of the 13R1 allele of the COL2A1 gene was included
in the logistic regression models to test for gene interaction.
All statistical analyses were done using the SPSS package
V.10 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
General characteristics of the study population are present in
table 1. BMI was similar in each group and was significantly
higher in cases than in controls except for subjects in the age
group older than 65 years. BMD tended to be higher in cases
than in controls, though the difference was not statistically
significant. The prevalence of ROA at all joint sites was higher
in subjects older than 65 years. The frequency of carriers of
the 13R1 allele of the COL2A1 gene VNTR polymorphism was
higher (though not significantly so) in ROA cases than in
controls.
The IGF-I allele frequencies were 66.2%, 18.6%, 6.7%, 4.6%,
and 3.9% for the 192 bp, 194 bp, 196 bp, 190 bp, and the
remaining alleles, respectively. Genotype frequencies accord-
ing to the 192 bp allele and risk estimates are presented in
table 2. In the overall study population, absence of the 192 bp
allele increased the risk for ROA, although the increase was
not statistically significant under a multiplicative model (p
for trend = 0.14). In the subjects aged 65 years or younger,
the absence of the 192 bp allele was related to significantly
increased risk for ROA (p for trend = 0.03), suggesting an
allele dose effect. Compared with homozygotes for the 192 bp
allele, the prevalence of ROA was 1.4 times increased for
heterozygotes (95% CI, 1.0 to 1.8) and 1.9 times for non-
carriers of the allele (95% CI, 1.1 to 3.3). This effect of the
IGF-I polymorphism was independent of BMD, BMI, age,
and sex. In the group of subjects older than 65 years, no
significant effect was observed (p for trend = 0.34).
No significant evidence for interaction between the IGF-I
gene and the COL2A1 gene was observed (p = 0.20).
However, the prevalence of ROA increased significantly (OR
3.4 (95% CI, 1.1 to 10.7)) only in non-carriers of the 192 bp
allele at the promoter region of the IGF-I gene who also
carried the 13R1 allele of the VNTR polymorphism in the
COL2A1 gene (fig 1). Here also, the effect of the IGF-I
polymorphism was independent of BMD, BMI, age, and sex.
When looking at the COL2A1 genotypes obtained from
hybridisation analysis, the interaction effects for both the 4A
and 4B alleles were—although not statistically significant—
in the same direction and magnitude as those observed for
the 13R1 interaction effect (OR 5.1 (95% CI, 0.6 to 41) for 4A
carriers without the IGF-I 192 bp allele; and OR 3.5 (0.4 to
29) for 4B carriers without the IGF-I 192 bp allele).
DISCUSSION
In this population based study we found that the absence of
the 192 bp allele of a microsatellite polymorphism in the
promoter region of the IGF-I gene was associated with
increased prevalence of radiographic osteoarthritis in subjects
aged 65 years or younger. Compared with homozygotes for
IGF-I and COL2A1 gene polymorphisms and osteoarthritis 545
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the 192 bp allele, the prevalence of ROA was higher in
heterozygotes (OR 1.4 (95% CI, 1.0 to 1.8)) and non-carriers
of the allele (OR 1.9 (1.1 to 3.3)). This effect most probably
occurs in interaction with the COL2A1 gene, as the
prevalence of ROA increased in individuals with the risk
genotype of both genes (OR 3.4 (95% CI, 1.1 to 10.7)). These
findings were independent of age, sex, BMI, and BMD. No
such effect was observed in subjects older than 65 years.
Spurious associations can result from population stratifica-
tion either because of a recent admixture of a different
population or because of inappropriate matching of patients
and controls.39 40 The occurrence of spurious associations in
our study is unlikely41 as cases and controls were sampled
from the same (ethnically homogeneous) source popula-
tion.31 Potential bias may arise from the fact that the IGF-I
and COL2A1 gene polymorphisms were not genotyped in all
subjects. However, there is no evidence of introduction of
selection bias as IGF-I and COL2A1 genotypes were missing
at random—as suggested by the fact that genotype frequen-
cies were in Hardy–Weinberg equilibrium proportions, and
allele frequencies were similar to those reported previously in
other white populations.35 36
Though we have used a different analytical approach to
pool alleles based on the presence or absence of the 192 bp
(wild type) allele, our current findings are consistent with the
association reported previously between the 194 bp allele (the
second most frequent allele in our study population) and
ROA.25 We did not undertake further allele specific analysis
because of lack of power, considering the low frequencies of
all the other alleles. We used this approach given our earlier
findings of lower serum IGF-I concentrations in the absence
of the 192 bp allele.26 Our results suggest that lower serum
concentrations of IGF-I may contribute to the pathogenesis of
early onset osteoarthritis (before the age of 65 years) by
causing decreased synthesis of matrix components in
articular cartilage.
Why this IGF-I polymorphism does not explain the
occurrence of osteoarthritis in the elderly remains to be
determined. One possible explanation is that the incidence of
osteoarthritis increases so markedly after the age of 65 years,
owing to the influence of other environmental factors, that
the contribution of genetic predisposition to disease onset is
reduced. Also, IGF-I stimulation of chondrocyte matrix
production has been shown to decrease with age,20 and this
may explain why genetically determined low IGF-I levels are
not relevant to the prevalence of ROA in old age. In addition
to these biological explanations, we cannot exclude lack of
power to detect any existing association in view of the
relatively small number of individuals older than 65 years in
our study.
Our results suggest that a genetic predisposition involving
IGF-I expression increases the risk of ROA. It remains to be
determined whether the polymorphism we studied is the
causal variant in IGF-I explaining the association, or if it is in
linkage disequilibrium with another polymorphism involved
in the pathology.
In early life, IGF-I has been shown to be a major stimulator
of type II collagen production.42 Furthermore, there is
evidence that IGF-I may be concerned in ROA through a
pathway involving the cartilage matrix.43 The finding of
increased prevalence of ROA in only those individuals with
both risk genotypes supports the possibility of a biological
interaction between the IGF-I and COL2A1 genes in the
development of osteoarthritis. Although the evidence for a
statistical interaction was not significant, it should be borne
in mind that the power of our study was low given the small
number of cases and controls (especially with genotypes
obtained from the heteroduplex analysis, where the numbers
Table 1 General characteristics of the study populations
Association study

















Age (years) 63.4 (4.1) 61.1 (3.9) 60.7 (2.7) 59.6 (2.7) 67.5 (1.4) 67.1 (1.6) 60.5 (2.7) 59.5 (2.8)
Female (%) 58.7* 50.3 60.7 54.5 55.6* 32.4 60.8 50
Height (cm) 168.5 (8.5) 169.8 (9.4) 168.6 (8.6) 169.7 (9.4) 168.4 (8.4) 170.3 (9.5) 168.7 (8.4) 169.8 (9.1)
Weight (kg) 75.2 (12.1) 72.0 (11.8) 75.5 (12.5)1 71.8 (12.2) 74.8 (11.3) 72.9 (9.8) 72.5 (12.4)* 72.5 (11.9)
BMI (kg/m2) 26.5 (3.7) 25.0 (3.3) 26.5 (3.8) 24.8 (3.2) 26.4 (3.7) 25.2 (3.5) 26.5 (3.7 25.1 (3.2)
BMD (g/cm2) 0.86 (0.13) 0.84 (0.13) 0.87 (0.13) 0.85 (0.13) 0.84 (0.13) 0.81 (0.11) 0.87 (0.13) 0.86 (0.12)
COL2A1 13R1+ (%) – – – – – – 67.0 64.0
Hand ROA (%) 60.8 – 57.3 – 66.8 – 57.3 –
Knee ROA (%) 17.6 – 15.9 – 20.5 – 18.1 –
Hip ROA (%) 10.9 – 8.0 – 15.7 – 9.3 –
Disk degeneration of
spine (%) 69.2 – 63.9 – 78.0 – 61.7 –
Values are mean (SD) unless stated otherwise.
*p,0.05, p,0.0001.
BMD, bone mineral density; BMI, body mass index; ROA, radiographic osteoarthritis.
Table 2 Association analysis












(n = 37) OR (95%CI)
Homozygous for 192 bp (%) 594 (43.8) 93 (48.7) Reference 344 (42.1) 79 (50.3) Reference 250 (46.5) 14 (37.8) Reference
Heterozygous for 192 bp (%) 593 (43.8) 78 (40.8) 1.2 (0.9 to 1.5) 368 (45.0) 60 (38.2) 1.4 (1.0 to 1.8) 225 (41.8) 18 (48.6) 0.8 (0.5 to 1.3)
Non-carriers of 192 bp (%) 168 (12.4) 20 (10.5) 1.4 (0.9 to 2.4) 105 (12.9) 15 (9.6) 1.9 (1.1 to 3.3) 63 (11.7) 5 (13.5) 0.6 (0.2 to 1.7)
p for trend ,0.05.
OR, odds ratio adjusted for age, sex, body mass index, and bone mineral density.
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were even smaller after splitting the COL2A1 13R1 carriers
into two subgroups).
Conclusions
Our study shows that the absence of the 192 bp allele in the
promoter region of the IGF-I gene is associated with
increased prevalence of radiographic osteoarthritis before
the age of 65 years. The study also suggests the possibility of a
genetic interaction between the IGF-I and the COL2A1 genes
in the occurrence of this disease.
ACKNOWLEDGEMENTS
This work was supported by the Netherlands Organisation for
Scientific Research (NWO) and was part of GZ’s MSc training
programme in Genetic Epidemiology at the Netherlands Institute for
Health Sciences (NIHES). We would like to thank A Bertoli MD, T
Rademaker, L Testers, J Vergeer-Drop, and R Oskamp for their help in
genotyping and data management.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
J J Houwing-Duistermaat, A Hofman, C M van Duijn, Department of
Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam,
Netherlands
J B J van Meurs, A G Uitterlinden, H A P Pols, Department of Internal
Medicine, Erasmus Medical Centre
I Meulenbelt, P E Slagboom, Department of Molecular Epidemiology,
Leiden University Medical Centre, Leiden, Netherlands
C Bijkerk, Department of Rheumatology, University Medical Centre St
Radboud, Nijmegen, Netherlands
F Rivadeneira, Instituto de Genetica Humana, Facultad de Medicina,
Pontificia Universidad Javeriana, Bogota, Colombia
G Zhai, Netherlands Institute for Health Sciences, Rotterdam,
Netherlands
REFERENCES
1 Felson D. Epidemiology of osteoarthritis. In: Beal K, eds. Osteoarthritis.
Oxford: Oxford University Press, 1998:13–22.
2 van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA.
Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of
radiological osteoarthritis in a Dutch population with that in 10 other
populations. Ann Rheum Dis 1989;48:271–80.
3 Howell DS. Pathogenesis of osteoarthritis. Am J Med 1986;80:24–8.
4 Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al.
Osteoarthritis: new insights. Part 1. The disease and its risk factors. Ann Intern
Med 2000;133:635–46.
5 Stecher R. Heberden’s nodes. Heredity in hypertrophic arthritis of the finger
joints. Am J Med Sci 1941;201:801–5.
6 Kellgren JHLJ, Bier F. Genetic factors in generalized osteoarthrosis. Ann
Rheum Dis 1963;22:237–55.
7 Spector TD, Cicuttini F, Baker J, Loughlin J, Hart D. Genetic influences on
osteoarthritis in women: a twin study. BMJ 1996;312:940–3.
8 Hirsch R, Lethbridge-Cejku M, Hanson R, Scott WW, Reichle R, Plato CC, et al.
Familial aggregation of osteoarthritis: data from the Baltimore longitudinal
study on aging. Arthritis Rheum 1998;41:1227–32.
9 Felson DT, Couropmitree NN, Chaisson CE, Hannan MT, Zhang Y,
McAlindon TE, et al. Evidence for a Mendelian gene in a segregation analysis
of generalized radiographic osteoarthritis: the Framingham Study. Arthritis
Rheum 1998;41:1064–71.
10 Bijkerk C, Houwing-Duistermaat JJ, Valkenburg HA, Meulenbelt I, Hofman A,
Breedveld FC, et al. Heritabilities of radiologic osteoarthritis in peripheral
joints and of disc degeneration of the spine. Arthritis Rheum
1999;42:1729–35.
11 MacGregor AJ, Antoniades L, Matson M, Andrew T, Spector TD. The genetic
contribution to radiographic hip osteoarthritis in women: results of a classic
twin study. Arthritis Rheum 2000;43:2410–16.
12 Loughlin J. Genetic epidemiology of primary osteoarthritis. Curr Opin
Rheumatol 2001;13:111–16.
13 Chapman K, Mustafa Z, Irven C, Carr AJ, Clipsham K, Smith A, et al.
Osteoarthritis-susceptibility locus on chromosome 11q, detected by linkage.
Am J Hum Genet 1999;65:167–74.
14 Loughlin J, Mustafa Z, Irven C, Smith A, Carr AJ, Sykes B, et al. Stratification
analysis of an osteoarthritis genome screen-suggestive linkage to
chromosomes 4, 6, and 16. Am J Hum Genet 1999;65:1795–8.
15 Leppavuori J, Kujala U, Kinnunen J, Kaprio J, Nissila M, Heliovaara M, et al.
Genome scan for predisposing loci for distal interphalangeal joint
osteoarthritis: evidence for a locus on 2q. Am J Hum Genet 1999;65:1060–7.
16 Wright GD, Hughes AE, Regan M, Doherty M. Association of two loci on
chromosome 2q with nodal osteoarthritis. Ann Rheum Dis 1996;55:317–19.
17 Osborn KD, Trippel SB, Mankin HJ. Growth factor stimulation of adult
articular cartilage. J Orthop Res 1989;7:35–42.
18 Tyler JA. Insulin-like growth factor 1 can decrease degradation and promote
synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J
1989;260:543–8.
19 Corpas E, Harman SM, Blackman MR. Human growth hormone and human
aging. Endocr Rev 1993;14:20–39.
20 Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ, Sonntag WE.
Reduction in the chondrocyte response to insulin-like growth factor 1 in aging
and osteoarthritis: studies in a non-human primate model of naturally
occurring disease. Arthritis Rheum 2000;43:2110–20.
21 Lloyd ME, Hart DJ, Nandra D, McAlindon TE, Wheeler M, Doyle DV, et al.
Relation between insulin-like growth factor-I concentrations, osteoarthritis,
bone density, and fractures in the general population: the Chingford study.
Ann Rheum Dis 1996;55:870–4.
22 Hochberg MC, Lethbridge-Cejku M, Scott WW, Reichle R, Plato CC, Tobin JD.
Serum levels of insulin-like growth factor in subjects with osteoarthritis of the
knee. Data from the Baltimore Longitudinal Study of Aging. Arthritis Rheum
1994;37:1177–80.
23 Schneiderman R, Rosenberg N, Hiss J, Lee P, Liu F, Hintz RL, et al.
Concentration and size distribution of insulin-like growth factor-I in human
normal and osteoarthritic synovial fluid and cartilage. Arch Biochem Biophys
1995;324:173–88.
24 McAlindon TE, Teale JD, Dieppe PA. Levels of insulin related growth factor 1 in
osteoarthritis of the knee. Ann Rheum Dis 1993;52:229–31.
25 Meulenbelt I, Bijkerk C, Miedema HS, Breedveld FC, Hofman A,
Valkenburg HA, et al. A genetic association study of the IGF-1 gene and
radiological osteoarthritis in a population-based cohort study (the Rotterdam
Study). Ann Rheum Dis 1998;57:371–4.
26 Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, et al. A
polymorphism in the gene for IGF-I: functional properties and risk for type 2
diabetes and myocardial infarction. Diabetes 2001;50:637–42.
27 Bijkerk C. Genetic epidemiology of osteoarthritis. In: Association of the
COL2A1 gene with radiological osteoarthritis in a population-based study: the
Rotterdam study. Erasmus University Rotterdam: Rotterdam, 1999:61–76.
28 Uitterlinden AG, Burger H, van Duijn CM, Huang Q, Hofman A,
Birkenhager JC, et al. Adjacent genes, for COL2A1 and the vitamin D
receptor, are associated with separate features of radiographic osteoarthritis
of the knee. Arthritis Rheum 2000;43:1456–64.
29 Loughlin J, Irven C, Fergusson C, Sykes B. Sibling pair analysis shows no
linkage of generalized osteoarthritis to the loci encoding type II collagen,
cartilage link protein or cartilage matrix protein. Br J Rheumatol
1994;33:1103–6.
30 Vikkula M, Nissila M, Hirvensalo E, Nuotio P, Palotie A, Aho K, et al.
Multiallelic polymorphism of the cartilage collagen gene: no association with
osteoarthrosis. Ann Rheum Dis 1993;52:762–4.
31 Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of
disease and disability in the elderly: the Rotterdam Elderly Study.
Eur J Epidemiol 1991;7:403–22.
32 Burger H, van Daele PL, Algra D, van den Ouweland FA, Grobbee DE,
Hofman A, et al. The association between age and bone mineral density in
men and women aged 55 years and over: the Rotterdam Study. Bone Miner
1994;25:1–13.
33 E Odding. Locomotor disability in the elderly. Erasmus University Rotterdam,
the Netherlands: Rotterdam, 1994.
34 Kellgren JHJM, Ball J, eds. Atlas of standard radiographs of arthritis. In: The
epidemiology of chronic rheumatism. Oxford: Blackwell Scientific
Publications, 1963.
35 Weber JL, May PE. Abundant class of human DNA polymorphisms which can
be typed using the polymerase chain reaction. Am J Hum Genet
1989;44:388–96.
Figure 1 Interaction between the IGF-I and COL2A1 genes in the
occurrence of radiographic osteoarthritis (ROA). Risk estimates adjusted
for age, sex, body mass index, and bone mineral density. *Total number
by genotype and percentage of subjects with ROA. bp, base pair; CI,
confidence interval; OA, osteoarthritis.
IGF-I and COL2A1 gene polymorphisms and osteoarthritis 547
www.annrheumdis.com
36 Berg ES, Olaisen B. Characterization of the COL2A1 VNTR polymorphism.
Genomics 1993;16:350–4.
37 Uitterlinden AG, Huang Q, Pols HA, van Leeuwen JP. Population analysis of
the collagen type IIalpha 1 39 variable number of tandem repeat
polymorphism by heteroduplex genotyping. Electrophoresis 1998;19:661–6.
38 van Meurs JB, Arp PP, Fang Y, Slagboom PE, Meulenbelt I, van Leeuwen JP,
et al. Detection of sequence variability of the collagen type IIalpha 1 39
variable number of tandem repeat. Electrophoresis 2000;21:3571–7.
39 Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3,5,13,14 and type 2
diabetes mellitus: an association in American Indians with genetic admixture.
Am J Hum Genet 1988;43:520–6.
40 Lander ES, Schork NJ. Genetic dissection of complex traits. Science
1994;265:2037–48.
41 Hottenga JJ, Houwing-Duistermaat JJ, van Duijn CM. [Roaming
through methodology. XXXVII. Unintentional population stratification
in genetic case-control studies]. Ned Tijdschr Geneeskd
2002;146:17–22.
42 Willis DH, Liberti JP. Post-receptor actions of somatomedin on chondrocyte
collagen biosynthesis. Biochim Biophys Acta 1985;844:72–80.
43 Denko CW, Boja B, Moskowitz RW. Growth promoting peptides in
osteoarthritis: insulin, insulin-like growth factor-1, growth hormone.
J Rheumatol 1990;17:1217–21.
ECHO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .







com] for a link
to the full text
of this article.
A
lthough most health professionals accept that randomisation in clinical trials is
important there is evidence that patients may not understand randomisation (either
the word or the concept) and may not accept its validity. A study in North
Staffordshire UK has shown that, while most people understand randomisation, many do
not accept it.
The participants were 130 students at five further education and leisure courses. They
varied in age from 18 to 70 years (mean 32 years) and in occupation from unskilled to
professional. Two thirds were women. Participants were given two scenarios, one medical
(referral to a consultant nearby or far away) and one non-medical (a free trip locally or to
Spain) and asked to say which of five methods of allocation were random. The methods
were selection by computer with no information about individuals, toss of a coin, drawing
paper slips out of a hat, individual choice, and alternate allocation in turn. They were then
asked to imagine they had been asked to take part in a clinical trial comparing two drugs,
each of them known to be of value, to try to find out which drug was the better. The five
methods of allocation were stated again and participants were asked to decide whether each
method was acceptable. (It was left open whether that meant acceptable to the participant
as a patient or acceptable as a feature of the trial.) Half of the participants were given a
written justification for randomisation in clinical trials and half were not.
Most participants (73–92%) considered computer allocation, coin tossing, and drawing
from a hat to be random methods. Most (77–92%) considered patient choice to be non-
random. Participants were divided about allocation in turn. The answers were similar for the
medical and the non-medical scenario. On the whole most people did not find any method
of randomisation acceptable in a clinical trial. Among those who judged the randomness of
each of the five methods correctly a minority (around one third) considered randomisation
acceptable. Three quarters of the group considered that asking the patients to choose their
own allocation was acceptable. When written justification of randomisation was given, the
proportion of participants considering computer allocation to be acceptable rose to 58% but a
majority still considered tossing a coin or drawing from a hat unacceptable.
Members of the general public mostly understand randomisation but balk at its use in
clinical trials. Methods such as tossing a coin or drawing from a hat are considered too
frivolous for medical use but computer allocation, after explanation, is more acceptable.
This Echo has also been published in the Postgraduate Medical Journal 2004;80:248.
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